Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival - Wikidata - awgldk - TriplyDB

Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival

Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival

http://www.wikidata.org/entity/Q36747210

about

Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective Systemic therapies for pancreatic cancer--the role of pharmacogenetics Genetic factors affecting patient responses to pancreatic cancer treatment FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells Algorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacy The increasing role of pharmacogenetics in the treatment of gastrointestinal cancers.Hypoxia-induced deoxycytidine kinase expression contributes to apoptosis in chronic lung disease.dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.Gemcitabine for the treatment of advanced nonsmall cell lung cancer Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.Patient-derived xenograft models: an emerging platform for translational cancer research Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.PharmGKB summary: gemcitabine pathway Genexol inhibits primary tumour growth and metastases in gemcitabine-resistant pancreatic ductal adenocarcinoma Clinical pharmacology and pharmacogenetics of gemcitabine.Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography Treatment of pancreatic cancer: what can we really predict today?Post-transcriptional controls by ribonucleoprotein complexes in the acquisition of drug resistance.The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting.dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer.RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients.A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.Drug metabolism and pancreatic cancer.Clinicopathological significance of deoxycytidine kinase expression in esophageal squamous cell carcinoma.HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment.Challenges of drug resistance in the management of pancreatic cancer.HuR's role in gemcitabine efficacy: an exception or opportunity?Genomics and pharmacogenomics of pancreatic adenocarcinoma.Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer.

P2860

Q26752368-92E6DA15-0C98-455F-97BA-4F30F8A3744C Q27021716-722A8DBB-A06F-4B49-BE99-D8B128E8CF33 Q28075293-34C163FF-374B-48D8-A49B-7D871CCFF1BE Q28075540-B9BBBE47-51A4-4080-9A99-4A3880876EEF Q28308112-13C68E23-4223-45F8-8F02-9267D947750D Q28481440-472DAA4C-E740-42F2-B6D8-D7AFC7B7BB3C Q28484288-5BC60083-FFDA-493D-9C69-5F5DEFEA02C8 Q33591937-937EA62F-51EB-4A43-9139-55CEC965E9AD Q33713383-D6DDAE90-DD4D-4A6D-8F11-B019C00A7646 Q33727842-7CE9F5AA-72D6-4E7B-B089-C4712A9CB733 Q33915997-5BBCC83B-1E05-4922-A5CF-9F9002D02ECD Q34177223-BA54362E-1D27-4208-9D45-25BB862528B8 Q34205518-C7D163A3-BAE5-467C-B69E-E327CCBEB2A8 Q34254837-BAC08BD0-0F7B-4567-BA2E-2AE46D87AEC1 Q34260205-F0B18F1C-C31A-4A6A-8688-A0A7BD392F4E Q34435450-879B5DDF-51B5-44CA-A26D-539C8B1133BF Q34625514-C76D3D9B-B015-4AF6-9C8E-9574D8D826F3 Q34985979-D4A429EB-C683-4BFB-833B-CA5E1F7CB535 Q35671422-57E82225-7E36-4613-923D-6700E9F0B677 Q36201693-E43CC112-182F-4F1D-9426-745AD86818D8 Q36610851-A884BB2B-037A-4E3C-9DCD-9255901E70B2 Q36859193-74061ED3-250B-40F9-B169-E13983633C89 Q37066258-4B52A9DC-ED7A-47EE-A4D3-55C78D7EA57F Q37085729-85B22873-A039-460A-A679-2331AC97FB1D Q37129815-223D3564-E3D3-44EB-9FE2-CC7FCCD14979 Q37139289-A877D16F-3E79-44FB-9EFA-36D3379751DE Q37156381-737A74C9-CCA2-4B87-8E8E-412ABF91C376 Q37207004-EF3F6814-1433-4A71-833D-F30E6649583E Q37249378-6DE36812-F1F7-4F6A-94E2-177A8AC624AD Q37253577-9261BE95-DA0A-472C-98AD-94D99B641649 Q37268613-0CE0683A-DF66-450A-9397-07D0250957C4 Q37347966-6E93A01C-69A4-4143-B336-5FD65DD1347E Q37542844-D503B23B-AF75-4814-A5FB-EF3D38608BE4 Q37559699-3B98D794-971B-45AA-AF95-F9B4D74FBA96 Q37614579-8166F478-8961-4B7E-BEBE-F393A97769CC Q37799830-B5A0BBC5-FBE2-4D70-A743-A7C5C8F77515 Q37940426-FF165E26-2082-4CCB-8E67-D9BDC88167BD Q37970279-4A35C17B-160E-49B0-AA24-7694E82B40B2 Q37994505-F50CE7A6-1164-4958-A7C8-F7335025B347 Q38075827-6CF57F8B-3472-4CAD-9CBE-93C1408BA542

P2860

Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival

http://www.wikidata.org/entity/Q36747210

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Immunohistochemical and geneti ...... tabine resistance and survival

@en

type

label

Immunohistochemical and geneti ...... tabine resistance and survival

@en

prefLabel

Immunohistochemical and geneti ...... tabine resistance and survival

@en

P1433

Q36747210-E83D936A-7D71-4F33-882D-2B57A8308F39

P1476

Q36747210-2ED8417B-D882-4838-8A45-D3926BC150A7

P2093

Q36747210-0FCE79F1-30DC-4B31-A9B9-3837CA07F4A1

Q36747210-2F9C83F4-E3F1-4FC1-A477-28EED6BDEA8B

Q36747210-4815FBFB-670A-42C5-8FBA-B937B66DF4F4

Q36747210-4CBEBBE0-8D46-4DC3-8E41-36C130784F01

Q36747210-68B88B8F-8C71-4D5B-B135-A7AF57989150

Q36747210-83FA7A17-2765-4BB4-A369-836FA83CD456

Q36747210-DCF56C11-6DA4-4B79-B87C-709FEA16DEC0

Q36747210-F4639EF8-98CC-48ED-AFA9-5B9242D66214

P2860

Q36747210-035FEB9F-DC37-44C3-A226-D6F17ED945F6

Q36747210-06BDC000-67EC-428A-9436-72BF94F5F38D

Q36747210-1A6ED518-1037-48EF-9F0F-095B43D6993F

Q36747210-1E0FA95E-773E-4C7B-9B6F-009C84C85356

Q36747210-25BF3EFA-5046-449E-87EA-8421842D141A

Q36747210-29454BBB-2FA4-406A-973E-89DD4F1BDE02

Q36747210-2CF7A585-9777-4D74-8F4B-919E20EF8488

Q36747210-3845513B-F606-4947-9B11-3C9B83DF37E1

Q36747210-3A27DBF2-0DCD-43DB-8E2B-8814E77C0607

Q36747210-479349B0-985B-434C-BFA3-FAE92AD58050

P304

Q36747210-6025D2CE-688E-4DC6-BAAA-AC59D2227F7C

P31

Q36747210-62858272-2F76-4271-9824-9C562798BDA5

P356

Q36747210-F0F5A539-9AA6-4210-A8C2-6CB615BAD56E

P407

Q36747210-DA9FAF45-EE0C-462B-9915-73F9C2B17CE6

P433

Q36747210-52261040-452C-445D-9FE1-47291D2D0A41

P478

Q36747210-0A0CECF8-24BB-413D-BD69-042A5263DDA7

P50

Q36747210-4D190C9F-4A1F-447D-8D2A-8D41E52A6D6C

P577

Q36747210-96F37B1A-DFF6-4936-A6EB-96DBA2EF5B6E

P698

Q36747210-59712160-D250-4643-80BE-C1C91869FA5D

P932

Q36747210-A53DA2FB-4FD4-4185-BE84-672E0376EF6A

P356

1078-0432.CCR-05-2655

P1433

Clinical Cancer Research

P1476

Immunohistochemical and geneti ...... tabine resistance and survival

@en

P2093

Alison Klein

http://www.w3.org/2001/XMLSchema#string

Belen Rubio-Viqueira

http://www.w3.org/2001/XMLSchema#string

Charles J Yeo

http://www.w3.org/2001/XMLSchema#string

Daniel Laheru

http://www.w3.org/2001/XMLSchema#string

Francesca Ricci

http://www.w3.org/2001/XMLSchema#string

Manuel Hidalgo

http://www.w3.org/2001/XMLSchema#string

Piotr Kulesza

http://www.w3.org/2001/XMLSchema#string

Valeria Sebastiani

http://www.w3.org/2001/XMLSchema#string

P2860

Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene

Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver

The intracellular localization of deoxycytidine kinase

Cancer statistics, 2005

An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma.

Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity.

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

A review of systemic therapy for advanced pancreatic cancer.

Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy.

Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.

P304

2492-2497

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-05-2655

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Christine A Iacobuzio-Donahue

P577

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16638857

http://www.w3.org/2001/XMLSchema#string

P932

3619210

http://www.w3.org/2001/XMLSchema#string